Goes
Goes
Goes, Netherlands35 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06292013 | |
| ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal cancer, rectal disorder, rectal neoplasm | Recruiting | Phase 3 | 2026-10-02 | NCT07188025 | |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-10-02 | NCT06307652 | |
| DUTCH Weight Control in Atrial Fibrillation Study | Arrhythmias, Cardiac, Body Weight, Body Weight Changes, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss, atrial fibrillation, cardiovascular disorder, heart disorder, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 4 | 2026-10-01 | NCT06184633 | |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Nutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, type 2 diabetes mellitus, vascular disorder | Recruiting | Phase 3 | 2026-09-30 | NCT07064473 | |
| A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 3 | 2026-09-30 | NCT04002297 | |
| Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma | B-cell neoplasm, Cardiotoxicity, Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, diffuse large B-cell lymphoma, heart disorder, heart failure, histiocytosis, immune system disorder, immunoproliferative disorder, injury, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasm, radiation injury | Recruiting | Phase 3 | 2026-09-23 | NCT06220032 | |
| Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | cardiovascular disorder, hypertensive disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-18 | NCT07181109 | |
| MAD Trial: Myopia Atropine Dose | Myopia, Progressive, degenerative myopia, eye disorder, myopia, refractive error | Active, not recruiting | Phase 3 | 2026-09-14 | NCT05667454 | |
| COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm | Recruiting | Phase 2 | 2026-09-11 | NCT05301881 | |
| Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-09-02 | NCT06652438 | |
| Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-08-21 | NCT03764553 | |
| Selatogrel Outcome Study in Suspected Acute Myocardial Infarction | acute myocardial infarction | Enrolling by invitation | Phase 3 | 2026-07-23 | NCT04957719 | |
| Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive | Female Contraception | Active, not recruiting | Phase 3 | 2026-06-08 | NCT06394999 | |
| Prospective Data Collection Initiative on Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Not stated | 2026-06-04 | NCT02070146 | |
| High-Risk prostatE Cancer radiatiOn Versus surgERy | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate adenocarcinoma, prostate cancer, prostate disorder | Recruiting | Not stated | 2026-05-22 | NCT05931419 | |
| SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, hereditary disease, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-05-22 | NCT05392608 | |
| A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-05-22 | NCT04628494 | |
| Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer | Breast Neoplasm Female | Active, not recruiting | Phase 3 | 2026-05-20 | NCT03425838 | |
| Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial | Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Recruiting | Not applicable | 2026-05-12 | NCT06434896 | |
| Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission | Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-03-06 | NCT05502250 | |
| Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-02-27 | NCT05581303 | |
| Leiden Thrombosis Recurrence Risk Prevention | Deep Vein Thrombosis, Embolism, Embolism and Thrombosis, Thromboembolism, Venous Thrombosis, cardiovascular disorder, lung disorder, pulmonary embolism, respiratory system disorder, thrombotic disease, vascular disorder, venous thromboembolism | Active, not recruiting | Not applicable | 2026-02-20 | NCT06087952 | |
| Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2025-12-03 | NCT07260435 | |
| Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2025-11-26 | NCT01898117 |